1127499-69-7

Upstream product

• 849758-12-9 methyl 4-bromo-3-fluorobenzoate 
• 375853-82-0 tert-Butyl 4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-3,6-dihydro-1(2H)-pyridinecarboxylate 

Downstream Products

• 1127499-72-2 4-(2-fluoro-4-methoxycarbonyl-phenyl)-piperidine-1-carboxylic acid tert-butyl ester 

Relevant academic research and scientific papers

BENZYL AMINE-CONTAINING 5,6-HETEROAROMATIC COMPOUNDS USEFUL AGAINST MYCOBACTERIAL INFECTION

A compound represented by formula (I):, or its pharmaceutically acceptable salt, wherein a group represented by formula: (II) is a group represented by formula: (III) or (IV); R1 is each independently halogen, hydroxy, cyano or the like; m is 0, 1, 2, 3 or 4; R2 is a hydrogen atom, halogen, cyano, substituted or unsubstituted alkyl or the like; R3a,R3b,R3c andR3d are each independently hydrogen atom, halogen or the like, with the proviso that R3a,R3b,R3c andR3d are not simultaneously hydrogen atom; ring C is represented as follows: (V), (VI), (VII), (VIII), (IX) or (X). X is CH or N; Y is CH or N; R4 is each independently halogen, hydroxy, cyano or the like; p is 0 or 1; q is 0, 1, 2, 3 or 4; R5 is CR5C or N; R6 is CR6C or N; R7 is CR7C or N; R8 is CR8C or N; R9 is CR9C or N; with the proviso that R5,R6,R7,R8 andR9 are not simultaneously N; R5C,R6C,R7C,R8C andR9C are each independently hydrogen atom or the like.

1',3'-DISUBSTITUTED-4-PHENYL-3,4,5,6-TETRAHYDRO-2H, 1'H-[1, 4'] BIPYRIDINYL-2'-ONES

The present invention relates to novel compounds, in particular novel pyridinone derivatives according to Formula (I) wherein all radicals are as defined in the application and claims. The compounds according to the invention are positive allosteric modulators of metabotropic receptors - subtype 2 ("mGluR2") which are useful for the treatment or prevention of neurological and psychiatric disorders associated with glutamate dysfunction and diseases in which the mGluR2 subtype of metabotropic receptors is involved. In particular, such diseases are central nervous system disorders selected from the group of anxiety, schizophrenia, migraine, depression, and epilepsy. The invention is also directed to pharmaceutical compositions and processes to prepare such compounds and compositions, as well as to the use of such compounds for the prevention and treatment of such diseases in which mGluR2 is involved.